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Abstract Chronic hepatitis C (CHC) is associated with
multiple extrahepatic manifestations that may impact
infected patients. The mechanisms through which these
develop include those which are immunological, in which
the chronic persistence of virus leads to the circulation of
immune complexes (mixed cryoglobulinemia) and other
autoimmune phenomena, and those which are virological
and related to the extrahepatic tropism of the virus to other
tissues. It is estimated that 40–74 % of patients with CHC
may develop at least one extrahepatic manifestation during
the course of the disease. Extrahepatic syndromes may
represent the first signal of hepatitis C infection in some
patients. CHC is associated with a four-fold increased risk
of insulin resistance and type 2 diabetes mellitus; with
cardiovascular disease in 17–37 % of patients; and with
increased risk for cerebrovascular deaths, with a biological
gradient of cerebrovascular mortality correlating with an
increasing serum viral load. CHC is also associated with
lymphoproliferative disorders, particularly non-Hodgkin
B-cell lymphoma. The kidney is involved in 35–60 % of
patients with CHC-associated mixed cryoglobulinemia.
The prevalent type of glomerulonephritis associated with
mixed cryoglobulinemia is membranoproliferative
glomerulonephritis. In 30 % of cases, renal involvement
begins with a nephritis syndrome and acute renal failure,
while in 55 % there is only mild hematuria, microalbu-
minuria, proteinuria and renal insufficiency. CHC is also
associated with cognitive impairment, especially in mem-
ory and concentration. Thus, extrahepatic CHC manifes-
tations involve multiple organ systems outside the liver
linked to a variety of comorbidities which may lead to
significantly increased mortality from non-liver-related
events.
Keywords Extrahepatic manifestations  Chronic
hepatitis C  Mixed cryoglobulinemia  Insulin resistance 
Diabetes mellitus  Lymphoproliferative disorder  HCV
brain syndrome  Renal failure
Introduction
The hepatitis C virus (HCV) has significant and obvious
hepatic implications. However, too often, the extrahepatic,
multi-organ ramifications of this virus are overlooked. Due
to the fact that HCV has been shown to infect both hepa-
tocytes and lymphocytes, lymphoproliferative diseases
such as lymphoma and mixed cryoglobulinemia (MC) are
most closely linked to hepatitis C infection [1]. However,
HCV has also been implicated in derangements of multiple
other organ systems including the integumentary, ocular,
muscular, skeletal, nervous, endocrine, cardiovascular,
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hepatitis C (CHC) has a crippling and debilitating psy-
chosocial effect. Clinical vigilance and acumen are needed
to recognize these extrahepatic manifestations (EMs) as
these may often be the initial findings in a patient previ-
ously undiagnosed with HCV infection. Studies have
demonstrated that up to 74 % of patients show at least one
EM [2].
The EMs can be divided into those with a high degree of
association with HCV and those with a more moderate or
mild association [3]. Some of the extrahepatic manifesta-
tions, including MC and non-Hodgkin B-cell lymphoma,
have significant prevalence and clear data supporting a
causal relationship. Other manifestations have been noted
to have a higher prevalence compared to controls in trials.
These include dermatological findings (porphyria cutanea
tarda), fatigue, cardiovascular disease (stroke, coronary
artery disease), renal involvement, and neurological dis-
orders (depression, impaired quality of life) [4].
Certain extrahepatic manifestations are known to occur in
patients with MC. These include palpable purpura, vasculitis,
arthralgias, and nephropathy [3]. However, these manifesta-
tions have also been reported without MC. For example,
patients with CHC have developed membranous nephropathy
in the absence of cryoglobulins or evidence of MC. Patients
with MC will often have elevated Rheumatoid Factors and
low complement levels which may serve as a means to dif-
ferentiate manifestations occurring secondary to MC [3].
Cryoglobulinemia and immune complex disease
Cryoglobulins are immunoglobulins that precipitate in vitro at
temperatures less than 37 C and often produce organ damage
via either a hyperviscosity syndrome or immune-mediated
mechanism [5]. Although cryoglobulinemia can be caused by
a wide variety of infections and disorders, CHC is known to
be the most common cause [6]. Three basic types of cryo-
globulinemias are recognized according to the clonality and
type of immunoglobulins. Type I consists of monoclonal
immunoglobulins, generally either IgM or IgG. Types II and
III are often referred to as mixed cryoglobulinemia (MC).
Type II cryoglobulins are a mixture of monoclonal IgM and
polyclonal IgG. Type III is a mixture of polyclonal IgM and
IgG. CHC is primarily associated with type II cryoglobu-
linemia [5] in which the primary mechanism of injury is
vasculitis that occurs via immune complex deposition. The
immunoglobulins produce immune complexes, which in turn
bind to the receptors on endothelial cells, allowing for sub-
sequent deposition and inflammation [5]. The vessels
involved are primarily small vessels and histopathologically it
is known as leukocytoclastic vasculitis.
Although the pathogenesis is not entirely understood,
cryoglobulinemia is markedly common in those with CHC.
In two separate studies, Lunel et al. and Pawlotsky et al.
found that 36–54 % of patients with CHC had
detectable cryoglobulins [7, 8]. Lunel et al. showed that
25 % of patients with CHC and cryoglobulins displayed
clinical symptoms which could be related to cryoglobu-
linemia [7]. Few organs are left unaffected by immune
complex deposition, with vasculitis occurring in the skin,
joints, kidneys, lungs, heart, digestive tract, and brain. In an
Iranian population, Jadali et al. found autoimmune disor-
ders associated with CHC that include Sjo¨gren syndrome,
thyroid disease, systemic lupus erythematosus, immune
thrombocytopenic purpura, and rheumatoid arthritis [9].
Patients with MC are also predisposed to malignancies,
specifically lymphoma as well as IgM paraproteinemia and
low-grade lymphoma, a syndrome known as Waldenstrom
macroglobulinemia [10]. Involvement with one or multiple
organs can present as a life-threatening manifestation.
Because MC occurs as a sequela of CHC, treatment is
aimed at the underlying disease process.
Renal involvement
Renal involvement is the most common severe manifesta-
tion of MC [11]. Given the increased propensity to develop
MC and subsequently renal disease, patients with CHC are
more likely to develop end-stage renal disease than the
general population [12]. Although other renal diseases have
been associated with CHC, chronic kidney disease occurs
most often in the context of MC [13]. However, direct
protein deposition of HCV RNA and associated proteins
has also been implicated in renal disease [13]. Renal
manifestations of CHC include Type I membranoprolifer-
ative glomerulonephritis (MPGN), mesangial glomeru-
lonephritis and focal and segmental glomerulonephritis. In
a China-based study, minimal change nephropathy and
membranous nephropathy were reported by Cheng et al.
[1]. Fibrillary glomerulonephritis, immunotactoid
glomerulopathy, IgA nephropathy, renal thrombotic
microangiopathy, vasculitic renal involvement and inter-
stitial nephritis have been reported in a Malaysian popu-
lation [12]. In one study of patients with CHC who
underwent biopsy, type I MPGN was the most common
finding associated with MC [11]. Ultimately, treatment is
directed at the underlying virus. Given the potentially fatal
sequelae of the aforementioned diseases, many clinicians
recommend annual screening for microalbuminuria,
microscopic hematuria, and cryoglobulinemia in patients
with CHC [12].
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Dermatological manifestations
Cacoub et al. found that 17 % of those with CHC displayed
a dermatological disorder, the most common being purpura
(7 %) and Raynaud’s phenomenon (7 %) [2]. Palpable
purpura, a non-blanching skin disorder, is the most com-
mon clinical manifestation of MC, occurring in up to 90 %
of cases [14]. Purpura, caused by an extravasation of red
blood cells into the dermis, is usually relegated to the
buttocks and lower extremities, with the face usually
spared. When small-to-medium-sized arterial vessels are
involved, polyarteritis nodosa may occur leading to an
infarct of the skin and subsequent irregular, often painful,
skin lesions [15]. Other immune complex-mediated skin
disorders include Raynaud’s phenomenon, which is char-
acterized by intermittent vasospasm triggered primarily by
cold environment or emotional stress. The vasospasm
causes cyanosis, blanching and often pain of the distal
digits. It can occur in up to one-third of cases and primarily
involves the hands, feet, lips, ears, and the tip of the nose
[14].
Many other skin disorders have been associated with
CHC, some with better established causality than others.
These disorders include porphyria cutanea tarda, lichen
planus, necrolytic acral erythema, erythema multiforme,
and pruritus. Less commonly reported skin manifestations
include psoriasis and sarcoidosis. Porphyria cutanea tarda,
caused by deficiency of hepatic uroporphyrinogen decar-
boxylase, is the most common porphyria. It is characterized
by painful vesicular lesions on sun-exposed regions of the
skin which rupture and eventually scar [15]. Lichen planus,
a mucocutaneous disorder, is also strongly associated with
CHC. Gandolfo et al. showed that, of their patients with
oral lichen planus, 62 % had HCV antibodies and 60 %
had HCV RNA [16]. A meta-analysis of 36 studies
regarding lichen planus and HCV showed that there was
also an increased risk of having lichen planus among CHC
patients [17]. Chronic lichen planus is considered a pre-
malignant condition, especially when involving the oral
cavity, and has the propensity to progress to squamous cell
carcinoma. Although data are limited on the effect of the
new direct acting antivirals on the cutaneous manifesta-
tions of CHC, there is evidence from earlier studies that
dermatological EMs including porphyria cutanea tarda
often resolve with treatment with pegylated interferon
(peg-IFN) and ribavirin [18–20]. Data on the treatment
effect on lichen planus, however, are conflicting, with both
worsening of manifestations and regression having been
reported [20].
Necrolytic acral erythema is thought to be the derma-
tological disorder that is most strongly associated with
CHC and is often considered to be pathognomonic for
CHC. It is characterized by painful or pruritic, erythema-
tous skin lesions involving acral skin surfaces [21].
Although the etiology is not entirely clear, necrolytic acral
erythema has been shown to improve with administration
of zinc [22]. Therefore, impairment in the regulation of
zinc, which can occur in CHC, is thought to be linked to
the pathogenesis [23].
Ocular manifestations
Several ocular manifestations that are secondary to
immunological mechanisms have been associated with
HCV. Disorders involving the anterior segment of the eye
include dry eye, Mooren ulcer, scleritis and episcleritis,
trichomegaly, and peripheral ulcerative keratopathy among
others. Posterior segment involvement can lead to multiple
disorders including cotton wool spots, retinopathy, central
vein thrombosis, crystal macular edema, nonarteritic
anterior ischemic optic neuropathy, and optic neuropathy
[24]. Of these, dry eye syndrome and ischemic retinopathy
seem to be the most common. Mooren ulcer is a rare ocular
complication associated with CHC. It is characterized by
progressive stromal ulceration. Although the pathogenesis
is not completely understood, it is thought to be an
autoimmune process against target antigens in the corneal
stroma [24].
Metabolic manifestations: diabetes and insulin
resistance
Metabolic disorders have been associated with CHC. Data
from the 1988 to 1994 NHANES cycle showed an inde-
pendent association of insulin resistance and diabetes with
HCV infection. In later NHANES cycles (1998–2008),
these associations were no longer found to be significant;
however, the relationship may have been diluted by the
increase of other risks for diabetes, most importantly the
rapid increase in the prevalence of obesity [25]. Multiple
other studies have shown a causal relationship between
CHC and insulin resistance, type 2 diabetes and subsequent
steatosis [26, 27]. Cheng et al. found that type 2 diabetes
mellitus was seen in 28 % of CHC patients, a significantly
higher prevalence compared to the study’s general popu-
lation [1]. Mehta et al. showed that CHC patients who were
at high risk for diabetes were more than 11 times as likely
as those without CHC to develop diabetes [28]. Another
study found that CHC is an independent predictor of dia-
betes [27]. Even with adjustment for other major predis-
posing conditions such as older age, obesity, and smoking,
CHC was associated with insulin resistance and diabetes.
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In a large longitudinal study that followed 4958 persons
from a community-wide cohort in southern Taiwan for
7 years, it was found that CHC, coinfection with hepatitis
B virus, overweight, obesity, and increasing age were
significantly associated with diabetes development [29].
Because with stratification by age and body mass index the
risk ratio for diabetes in CHC participants increased when
age decreased and body mass index levels increased, the
researchers concluded that HCV infection is an indepen-
dent predictor of diabetes, especially for CHC persons who
are younger or have a higher body mass index. In patients
treated with peg-IFN and ribavirin, it was found that in
patients with pre-treatment insulin resistance, insulin sen-
sitivity was improved at 12 weeks and 24 weeks, and at
end of therapy (24 or 48 weeks) [30]. The findings of both
cross-sectional and longitudinal studies [31] and a large
meta-analysis [32] have suggested a direct role of HCV in
inducing derangement of glucose metabolism. The mech-
anism of action is thought to be secondary to an effect on
glucose-insulin regulation, and lipid metabolism and syn-
thesis [27].
Salivary gland
Sjo¨gren syndrome is described as a chronic, slowly pro-
gressive autoimmune disease characterized by lymphocytic
infiltration of the exocrine glands and B-lymphocyte
reactivity resulting in xerostomia and dry eyes. Histologi-
cal changes characteristic of Sjo¨gren syndrome, focal
lymphocytic sialadenitis, were significantly more common
in CHC patients [33]. It is not entirely clear whether HCV
causes a Sjo¨gren-like illness or is responsible for the onset
of Sjo¨gren. Although sialadenitis is common, dry eyes and
dry mouth are often absent. Furthermore, although Sjo¨gren
syndrome causes periductal lymphocytic infiltration, CHC
patients are noted to have pericapillary lymphocytic infil-
tration [34]. Lymphoma is a well-known manifestation of
Sjo¨gren syndrome that usually presents later in the illness.
Most lymphomas are extranodal, low-grade marginal zone
B-cell lymphomas [15].
Malignancies
Several viruses have been linked to the development of
cancer. It has been estimated that 18.6 % of cancers
worldwide are attributable to five infections: Helicobacter
pylori (37.0 %), human papillomavirus (27.9 %), HCV
plus hepatitis B virus (24.8 %), and Epstein–Barr virus
(10.3 %) [35]. The burden of cancers related to organisms
is clearly more apparent in developing countries as com-
pared to developed nations. If infections linked to cancer
were eradicated there would be 26.3 % fewer cancers in
developing countries (1.5 million cases per year) and 7.7 %
fewer in developed countries (390,000 cases) [36].
Although hepatocellular carcinoma is the cancer most
commonly associated with HCV, it has been found that
several other malignancies are more common in those with
CHC compared to the general population. Prostate cancer
has been noted to correlate with detection of hepatitis C
antibody [37]. In a study of Japanese patients, both oral and
other digestive tract cancers were shown to correlate with
HCV infection [38]. As previously stated, squamous cell
carcinoma is associated with lichen planus. However, oral
verrucous and squamous cell carcinoma were reported in
CHC patients even without the presence of oral lichen
planus [34]. In patients with MC, CHC and autoimmune
thyroiditis, there is an increased prevalence of papillary
thyroid cancer [39].
The strongest association of CHC and cancers other than
HCC is with lymphoma, specifically diffuse large B-cell
non-Hodgkin lymphoma, the most common subtype of
lymphoma in the USA [40]. Due to the fact that tumor
regression occurs when antiviral therapy begins, it is
thought that CHC is directly responsible for tumor pro-
gression although the mechanism of how this occurs is not
entirely understood. Studies have also assessed the possi-
bility of an association between HCV and breast cancer. In
a large, population-based study in Taiwan, no significant
association was found between breast cancer risk and HCV
seropositivity; however, an age-stratification analysis con-
ducted by Su et al. in Taiwan found that HCV patients aged
less than 50 years had a two-fold greater risk of breast
cancer [41]. In a smaller study in France, chronic HCV
infection was not found to be a promoter of breast cancer in
adult females of any age [42].
Pulmonary fibrosis
Pulmonary fibrosis, manifesting most commonly as dysp-
nea on exertion and nonproductive cough, is histologically
characterized by interstitial inflammation, foci of prolifer-
ating fibroblasts, and dense collagen fibrosis [15]. Although
the pathogenesis is not clear, several studies have shown a
link between CHC and the development of pulmonary
fibrosis. A study of Japanese patients compared those with
CHC, chronic hepatitis B and a control group. It was found
that there was a higher prevalence of pulmonary fibrosis in
those with CHC compared to the other two groups [43]. In
another study, patients with a diagnosis of idiopathic pul-
monary fibrosis (IPF) were tested for antibodies to hepatitis
C virus via an enzyme-linked immunosorbent assay
(ELISA). More than 25 % were positive for the test and the
rate of CHC was higher in the patients with idiopathic
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pulmonary fibrosis compared to those who did not have
CHC [44]. Another study showed similar results with those
patients testing positive for HCV having an increasing
incidence of lung disease, the most common being IPF
[44].
Psychiatric manifestations
Patients with CHC have a higher prevalence of both mental
illness and substance abuse compared with the general
population [45, 46]. Given this, there have been recom-
mendations to screen patients with substance abuse disor-
ders and/or mental illness such as bipolar disorder, as the
relative risk for CHC is significantly higher than in those
without these conditions [47]. Although improving over
time, there is still a stigma associated with a diagnosis of
hepatitis C. In turn, patients may have feelings of embar-
rassment or shame leading to the delay or avoidance of
treatment. Feelings of depression or anxiety often accom-
pany the diagnosis. Given the increased prevalence of drug
abuse in the mentally ill population [48], it is hard to assess
whether depression is a sequela of the disease or a pre-
disposing factor. Furthermore, treatment compliance and
disease management are often compromised given the
underlying mental illness.
Studies have shown that patients with CHC are more
likely to have depression and an impaired quality of life
[49, 50]. In those who do seek treatment, achieving a
12-week sustained viral response (SVR) was found to be
protective for depression [51]. Furthermore, it was found
that patients with SVR had a better quality of life than
those who failed treatment [52]. Psychosocial assessment is
a crucial step in the overall management of CHC and is too
often overlooked. This assessment is clearly important for
quality of life and treatment compliance as psychosocial
impairment in HCV patients significantly affects treatment
adherence [53].
Thyroid involvement
Mao et al. reported that, in Chinese patients, thyroid dys-
function, including chronic thyroiditis, hypothyroidism and
hyperthyroidism, was associated with CHC [54]. The eti-
ology is primarily autoimmune and the prevalence of anti-
thyroid autoantibodies ranges from 4 to 15 % in CHC
infection [55]. Thyroid abnormalities, primarily Hashimo-
to’s disease and isolated increases of anti-thyroid anti-
bodies, appear to be more frequent in chronic hepatitis C
than in chronic hepatitis B or D [56]. Patients with MC and
CHC were more likely to have increased levels of serum
anti-thyroperoxidase autoantibody and anti-thyroglobulin
autoantibody than the general population. This is thought to
occur via a complex mechanism involving T helper cells
[39]. Patients with CHC are more susceptible than patients
with chronic hepatitis B to autoimmune thyroid disease.
Screening of thyroid gland function and an antibody panel
are recommended by some clinicians for all patients with
CHC [57].
Cardiovascular disease
According to the World Health Organization, ischemic
heart disease and stroke are the two leading causes of death
worldwide [58]. Coronary artery disease (CAD), peripheral
arterial disease (PAD) and cerebrovascular disease have all
been shown to be increased in those with CHC. Although a
recent systematic review has shown that the association
remains inconclusive, warranting the need for further
research [59], multiple studies including those in Asian
populations have shown that there is an increased risk of
stroke in those with CHC [60, 61] and CHC treatment
appears to decrease this risk [62]. In a study based in
Taiwan, there was an increased risk of stroke with
increasing serum HCV RNA levels; there was no associ-
ation between virus genotypes and risk [63]. Localization
of HCV RNA in human carotid plaques provides strong
evidence for an association between HCV and atheroscle-
rosis and suggests that the HCV RNA in plaque tissue is an
active local infection linked to tissue damage [64].
Inflammation and replication of the virus within both car-
otid plaques and brain endothelial cells have been found
and are thought to be key mediators [65]. CHC has been
shown to increase carotid thickness and/or plaque as seen
on ultrasonography [63].
Although CHC patients are less likely to have hyper-
tension and have lower mean total cholesterol, low-density
lipoprotein cholesterol and triglycerides, many studies have
shown that patients have an increased risk of CAD despite
this favorable risk profile [66, 67]. A Turkish study by
Alyan et al. involving patients with known CAD showed
that CHC patients had a higher level of C-reactive protein
and fibrinogen and that infection with the virus was an
independent predictor for severity of CAD [68]. A Tai-
wanese study showed that patients with CHC had an almost
1.5-fold higher risk of developing PAD than those without
HCV infection [69]. This number increased in patients with
increasing age and comorbidities such as chronic kidney
disease. Patients who were aged 65 and older had an almost
12-fold higher risk of developing PAD. Congestive heart
failure as a subtype of cardiovascular disease was also
shown to be increased in those with CHC. In another study,
patients with concomitant CHC and congestive heart fail-
ure were significantly younger than average for the
Hepatol Int (2016) 10:415–423 419
123
population [27]. In addition, patients with CHC have been
shown to have increased pulmonary vascular resistance and
pulmonary systolic pressure [70].
Neuropathies
Peripheral nerves are composed of sensory, motor, and
autonomic elements. Thus, peripheral neuropathies can
impair sensory, motor or autonomic function either singly or
in combination [15]. Peripheral neuropathies are further
classified into those that primarily affect the cell body,
myelin, and the axon [15]. HCV can affect all three portions
of the neuron, with CHC patients experiencing axonal neu-
ropathies such as sensorimotor polyneuropathy, large or small
fiber sensory neuropathy, motor polyneuropathy, and
mononeuritis, among others. Demyelinating disorders
including chronic inflammatory demyelinating polyneuropa-
thy, the Lewis-Summer Syndrome, and cryoglobulin-associ-
ated polyneuropathy are also associated with CHC [71].
CHC patients have been shown to have a higher
prevalence of sensory, motor and autonomic dysregulation
than the general population. The etiology is not entirely
clear. Some postulated causes include vitamin deficiency,
cryoglobulinemia and immune complex deposition, and
metabolic conditions such as diabetes which CHC patients
have an increased propensity to develop. Although alco-
holism and substance abuse are more common in those
with CHC and levels of B12 tend to be lower in these
groups of patients, one Egyptian study specifically showed
that neuropathy was not related to B12 and CHC was an
independent risk factor [72]. Another study showed that
peripheral neuropathy associated with mixed cryoglobu-
linemia secondary to CHC was related to the duration of
HCV infection and unrelated to the duration of cryoglob-
ulinemia [73].
Neurologic disorders
Similar to the other extrahepatic manifestations mentioned,
neurological manifestations are thought to be immune
mediated but may also occur through invasion of the virus
in neural tissue [71]. Researchers who have reported that
HCV sequences are detected in cerebrospinal fluid (CSF)
have noted that, in patients who have different virus strains
in serum and peripheral blood mononuclear cells (PBMC),
the CSF-derived virus is similar to that found in PBMC,
leading to the hypothesis that PBMC might carry HCV into
the brain [74]. Although most research has focused on
HCV replication in hepatocytes, several studies have pro-
vided evidence that HCV replication occurs in the central
nervous system, although probably at considerably lower
levels than in the liver [75, 76].
Negative-strand HCV RNA has been found in autopsy
brain tissue samples, with serum- and brain-derived viral
sequences shown to be different [75]. Furthermore, HCV
receptor expression is not exclusive to hepatocytes. It has
been reported that brain microvascular endothelial cells,
the major component of the blood–brain barrier, express all
receptors required for HCV entry [77]. In a study of
autopsy brain tissue, the brain cells that were found to
harbor HCV were mainly CD68? cells (macrophages/mi-
croglia) and, to a lesser extent, astrocytes [78].
The physical sequelae of CHC are often grossly apparent
but the cognitive dysfunction associated with this disease is
often missed. CHC has been associated with a poorer quality
of life secondary to neuropsychiatric and psychosocial prob-
lems, leading often to difficulties in management and subse-
quently in the course of the disease. A wide variety of
neurological manifestations have been shown to occur sec-
ondary to CHC. Cognitive impairment, particularly in power
of concentration and speed of working memory, that is
unaccounted for by depression, fatigue, or a history of injec-
tion drug use has been reported in CHC patients [79]. In their
Taiwan-based study, Chiu et al. found an increased incidence
of dementia in those with CHC after adjustment for variables
such as hepatic encephalopathy and alcohol-related disease
[80]. Another study showed executive functions (performance
on clock drawing study, digit span backward test, animal
verbal fluency test, and EXIT 25 test) to be impaired in those
with CHC [81]. In one study, a neurocognitive test, the
Repeatable Battery for the Assessment of Neuropsychological
Status, was administered to inmates with CHC to assess
cognitive functioning. Compared with the control group, those
with CHC performed at a significantly lower level [82]. A
study involving veterans showed that, when comorbidities and
substance abuse disorders were accounted for, there were
significant differences in memory, attention, processing of
information and reasoning in CHC patients [83].
Treatment effect
Although data are limited on the resolution of extrahepatic
manifestations with the new direct acting antiviral medica-
tions, multiple studies over the course of the past few decades
have shown marked improvement of EMs upon eradication of
HCV after treatment with previous therapies, primarily com-
bination therapy with peg-IFN and ribavirin. With standard
courses of peg-IFN/ribavirin the following have been seen:
• Reduced insulin resistance, with improved insulin
sensitivity seen at 12 weeks and 24 weeks, and at end
of therapy (24 or 48 weeks) [30].
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• Improved health-related quality of life [52, 84].
• Improved work productivity [84].
• Reduced depression [51].
• Resolution of dermatological EMs including porphyria
cutanea tarda [18–20] and lichen planus, although data
on the latter are conflicting with both worsening and
regression having been reported [20].
• Reduced stroke risk [62].
• Clearance of cryoglobulins with reduced risk of end
organ damage [85].
Emerging data on treatment with the direct acting
antivirals show similar effects. A recent study showed
decreased fatigue at SVR 12 compared to baseline with
treatment with ledipasvir and sofosbuvir [86]. Viral erad-
ication with sofosbuvir/ledipasvir has also been associated
with improvement in health-related quality of life and work
productivity [87].
Conclusion
Although commonly having the connotation of being a
disease of the liver, chronic infection with HCV has
the ability to cause significant extrahepatic manifesta-
tions affecting virtually every organ via a variety of
mechanisms. Awareness on the clinician’s part is
necessary to recognize these sequelae. This in turn can
lead to appropriate screening, early treatment and
improved outcomes. These systemic manifestations of
CHC may explain the increased all-cause mortality
that is seen even when excluding liver disease-asso-
ciated mortality.
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